Back to first-pass browser

First-pass extracted concept

zebrafish as an in vivo screening platform

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The review presents zebrafish as an in vivo platform for screening drugs and proteins across multiple biomedical use cases. It is positioned as a bridge between cell-line evidence and whole-organism evidence.

Source 1DOIPubMed

Resources required

Use of this platform requires zebrafish maintenance, embryo production, and phenotype-based or disease-model screening setups. The abstract also implies the need for genetically or phenotypically relevant zebrafish models.

Source 1DOIPubMed

What problem it solves

It helps address the need for more scalable in vivo screening and gene-function-related discovery than is practical in higher vertebrates. The platform is framed as reducing time and labor burdens relative to more complex animal systems.

Source 1DOIPubMed

What it does not solve

The abstract does not claim that zebrafish fully replace higher-vertebrate or clinical validation. It also does not specify that every human disease phenotype is faithfully modeled.

Source 1DOIPubMed

Alternatives

The review contrasts zebrafish mainly with in vitro cell lines and higher vertebrates. Zebrafish are presented as an intermediate platform between those options.

Source 1DOIPubMed

Evidence Snippets

Such merits have popularized the zebrafish as a model system for biomedical and pharmaceutical studies, including drug screening. Here, we reviewed the various ways in which zebrafish serve as an in vivo platform to perform drug and protein screening
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application scope summarysupports2021Source 1DOIPubMed

The review covers zebrafish screening applications in rare human diseases, social behavior, cancer studies, environmental pollutant detection, nanoparticle biosafety assessment, and QT prolongation assessment.

Quoted textsource-backed
we reviewed the various ways in which zebrafish serve as an in vivo platform to perform drug and protein screening in the fields of rare human diseases, social behavior and cancer studies. We also reviewed and described how zebrafish are used to carry out environmental pollutant detection and assessment of nanoparticle biosafety and QT prolongation.
Claim 2clinical translation summarysupports2021Source 1DOIPubMed

Many compounds identified from zebrafish screening systems have advanced to early clinical trials, including examples in adenoid cystic carcinoma, Dravet syndrome, and Diamond-Blackfan anemia.

Quoted textsource-backed
many compounds identified from zebrafish screening systems have advanced to early clinical trials, such as those for Adenoid cystic carcinoma, Dravet syndrome and Diamond-Blackfan anemia
Claim 3disease modeling summarysupports2021Source 1DOIPubMed

Zebrafish mutations can faithfully phenocopy many human disorders.

Quoted textsource-backed
Since zebrafish mutations faithfully phenocopy many human disorders
Claim 4platform advantage summarysupports2021Source 1DOIPubMed

Zebrafish offer practical and biological features that make them useful as an in vivo model system for biomedical and pharmaceutical screening.

Quoted textsource-backed
the lower vertebrate zebrafish possesses many advantages over higher vertebrates, such as low maintenance, high fecundity, light-induced spawning, transparent embryos, short generation interval, rapid embryonic development, fully sequenced genome, and some phenotypes similar to human diseases
Claim 5translational positioningsupports2021Source 1DOIPubMed

Zebrafish can bridge the gap between in vitro cell-line evidence and in vivo evidence in screening workflows.

Quoted textsource-backed
bridging the gap between in vitro evidence from cell lines and in vivo evidence, the lower vertebrate zebrafish possesses many advantages